Osteal Therapeutics

Recent Finacing

Series C

Recent Raise

$23M

Osteal Therapeutics is a clinical-stage biopharmaceutical company that develops novel musculoskeletal therapeutics to treat orthopedic infections, with its lead therapy, VT-X7, currently in Phase 2 development for chronic periprosthetic joint infections.

Total Funding

$23M

Headquarters

Dallas, USA

Founded

N/A

Website

ostealtx.com

Focus Areas

Biopharmaceutical

Orthopedic Infections

Drug Development

Investors